Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.

No link between thrombopoietin receptor agonists use and portal vein thrombosis in CLD

13 Jan 2019

Thrombopoietin receptor agonists (TPORAs) show no clear association with portal vein thrombosis (PVT) when used to treat patients with chronic liver disease (CLD), reports a recent meta-analysis.

A pooled analysis of four studies (n=1,953 CLD patients) showed that there was no significant increase in the incidence of PVT in patients treated with TPORAs compared with those who received placebo (odds ratio [OR], 2.8; 95 percent CI, 0.97–8.16; p=0.055).

The TPORAs tested in the studies were eltrombopag, avatrombopag and lusutrombopag. While there were no significant publication bias (p=0.4) and evidence of heterogeneity (p=0.718) among the studies, the correlation between PVT and TPORA use achieved statistical significance when analysis was restricted to patients treated with eltrombopag (OR, 3.8; 1.14–13.2; p=0.03).

Moreover, in two studies including 1,727 patients, the rates of arterial and venous thromboembolic events were 3.6 percent and 1.1 percent in those who received eltrombopag or placebo, respectively. This corresponded to a significant difference (OR, 3.4; 1.5–7.7; p=0.003).

In a subsequent analysis including three studies (n=514 patients), there was no significant link between TPORA use and PVT incidence in patients with liver disease and thrombocytopaenia undergoing elective invasive procedures (vs placebo: 2.8 percent vs 0.9 percent; OR, 2.6; 0.6–11.6; p=0.212). Heterogeneity and publication bias were likewise nonsignificant.

In the present meta-analysis, the databases of PubMed, SCOPUS, Cochrane and ISI Web of Science were accessed. Aside from case reports, commentaries, review articles and animal studies, papers that did not include an untreated control group were ineligible for inclusion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.